Go Pro
OTCMKTS:MCUJF

Medicure Q2 2026 Earnings Report

Medicure logo
$0.96 +0.05 (+5.36%)
As of 11:44 AM Eastern

Medicure EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$5.36 million
Expected Revenue
$2.45 million
Beat/Miss
Beat by +$2.91 million
YoY Revenue Growth
N/A

Medicure Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Medicure Earnings Headlines

The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.tc pixel
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) Pharmaceutical Corp. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of therapies in the cardiovascular and critical‐care markets. The company advances its business through a combination of in-licensing, acquisitions and strategic partnerships designed to build a diversified portfolio of prescription products that address unmet medical needs.

Headquartered in Montreal, Canada, Medicure operates in North America and selectively in Europe through licensing agreements with regional distributors. Its commercial portfolio includes branded cardiovascular products, while its research and development pipeline features small‐molecule candidates targeting acute heart failure, pulmonary hypertension and related conditions. The company leverages its regulatory and clinical expertise to shepherd assets from late‐stage development through to market access.

Since its founding in 2004, Medicure has grown by forging collaborations with both larger pharmaceutical companies and specialty distributors, aiming to accelerate product launches and maximize reach in key therapeutic segments. The senior leadership team brings decades of experience in drug development, regulatory affairs and commercial operations, positioning Medicure to advance its niche cardiovascular and critical‐care medicines to patients in need.

View Medicure Profile